title: [Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
abstract: Although surgery is treatment of choice for esophageal cancer, radiochemotherapy is being employed throughout Japan for the purpose of improving patient QOL. The results of this therapy are reported to be comparable to those associated with surgical treatment. However, since concomitant 5-FU/CDDP radiotherapy, currently the treatment of choice when implementing radiochemotherapy, is associated with a comparatively high incidence of gastrointestinal disorders and requires continuous intravenous infusion for 24 hours, it lowers the level of patient QOL. We have proposed a clinical study of concomitant TS-1/CDGP radiotherapy for the purpose of maintaining patient QOL and improving outcome. We conducted a pilot study prior to the phase I and II studies. The study was conducted on six cases and favorable results were obtained, consisting of a CR rate of 66.7% and a two-year survival rate of 50%. Although bone marrow inhibition was observed as an adverse side effect, gastrointestinal disorders that were discernible to the patients were extremely mild, and patient QOL was able to be maintained. CR was observed in 2 cases who were positive for DPD as determined by immunostaining. We are planning on conducting phase I and II studies in the future based on the potential for this treatment to contribute to the preservation of patient QOL and improve prognosis.
authors.affiliation: Division of Gastroenterology and Hepatology, Dept. of Internal Medicine, St. Marianna University, School of Medicine.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Inaba
authors.forename: Aya
authors.initials: A
authors.lastname: Miyazaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Tsuda
authors.forename: Hiroko
authors.initials: H
authors.lastname: Akasaka
authors.forename: Miyako
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Masaru
authors.initials: M
authors.lastname: Okamoto
authors.forename: Kyouko
authors.initials: K
authors.lastname: Ogihara
authors.forename: Shunichi
authors.initials: S
authors.lastname: Yamauchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Koro
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Katoh
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Fujita
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Abiko
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nakaya
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kitajima
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Hoshikawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kimura
authors.forename: Fumio
authors.initials: F
authors.lastname: Itoh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010094:Oxonic Acid / Q000008:administration & dosage; D010865:Pilot Projects; D011725:Pyridines / Q000008:administration & dosage; D011788:Quality of Life; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; C053989:nedaplatin